sulforaphene, sulphoraphene
| Name | Sulforaphene | ||
| PubChem CID | 6433206 | ||
| Molecular Weight | 175.3g/mol | ||
| Synonyms |
sulforaphene, sulphoraphene |
||
| Formula | C₆H₉NOS₂ | ||
| SMILES | CS(=O)C=CCCN=C=S | ||
| InChI | 1S/C6H9NOS2/c1-10(8)5-3-2-4-7-6-9/h3,5H,2,4H2,1H3/b5-3+ | ||
| InChIKey | QKGJFQMGPDVOQE-HWKANZROSA-N | ||
| CAS Number | 592-95-0 | ||
| ChEMBL ID | CHEMBL49659 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | LaiFuZi | ||
| Use Part | Seed | ||
| Habitat | China | ||
| Flavor | Pungent; Sweet | ||
| Meridian Tropism | Lung; Spleen; Stomach | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Dicotyledoneae
-->Order: Rhoeadales
-->Family: Brassicaceae
-->Genus: Raphanus
-->Species: Raphanus sativus
|
||
| Pair Name | Sulforaphene, Carboplatin | |||
| Partner Name | Carboplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Down-regulation | Expression | JUN | hsa3725 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| Result | This study demonstrates that the duel character of this combination therapy may be an effective replacement for conventional therapy alone against NSCLC. | |||
| Pair Name | Sulforaphene, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C73] | Ovarian Cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
| Up-regulation | Expression | CASP8 | hsa841 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| Up-regulation | Activity | PTEN | hsa5728 | |
| In Vitro Model | SK-OV-3 | Ovarian serous cystadenocarcinoma | Homo sapiens (Human) | CVCL_0532 |
| SNU-8 | Ovarian serous cystadenocarcinoma | Homo sapiens (Human) | CVCL_5096 | |
| Result | SFE synergistically inhibited proliferation and induced apoptosis of SKOV3 and SNU8 cells in combination with cisplatin by activating multiple apoptotic pathways. Therefore, we suggest sulforaphene as a chemo-enhancing adjuvant to improve the efficacy of cisplatin in ovarian cancer treatment. | |||
| Pair Name | Sulforaphene, Photodynamic therapy | |||
| Partner Name | Photodynamic therapy | |||
| Disease Info | [ICD-11: 2D10.Z] | Thyroid cancer | Investigative | |
| Biological Phenomena | Induction-->ROS generation | |||
| Gene Regulation | Down-regulation | Phosphorylation | BRAF | hsa673 |
| Down-regulation | Expression | KRAS | hsa3845 | |
| Down-regulation | Phosphorylation | MAP2K2 | hsa5605 | |
| Down-regulation | Phosphorylation | MAP2K7 | hsa5609 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Down-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| Down-regulation | Phosphorylation | MAPK3 | hsa5595 | |
| In Vitro Model | FRO | Thyroid gland anaplastic carcinoma | Homo sapiens (Human) | CVCL_6287 |
| Result | Our work designates sulforaphene as a unique natural enhancer of efficacy with PDT against anaplastic thyroid cancer. | |||
| Pair Name | Sulforaphene, Photodynamic therapy | |||
| Partner Name | Photodynamic therapy | |||
| Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CASP12 | hsa100506742 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Up-regulation | Expression | CASP8 | hsa841 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Up-regulation | Expression | DDIT3 | hsa1649 | |
| Down-regulation | Expression | EGFR | hsa1956 | |
| In Vitro Model | HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 |
| Result | This study could be useful in the improvement of therapies for human cervical and other types of cancers. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Sulforaphene-Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma. J Med Food. 2016 Sep;19(9):860-9. doi: 10.1089/jmf.2016.3675. | Click |
| 2 | Sulforaphene Synergistically Sensitizes Cisplatin via Enhanced Mitochondrial Dysfunction and PI3K/PTEN Modulation in Ovarian Cancer Cells. Anticancer Res. 2015 Jul;35(7):3901-8. | Click |
| 3 | Sulforaphene Enhances The Efficacy of Photodynamic Therapy In Anaplastic Thyroid Cancer Through Ras/RAF/MEK/ERK Pathway Suppression. J Photochem Photobiol B. 2018 Feb;179:46-53. doi: 10.1016/j.jphotobiol.2017.12.013. | Click |
| 4 | Evaluation of synergistic effects of sulforaphene with photodynamic therapy in human cervical cancer cell line. Lasers Med Sci. 2016 Nov;31(8):1675-1682. doi: 10.1007/s10103-016-2037-1. | Click |
